Overview

This On Demand Webinar was recorded live during the Medical Affairs and Scientific Communications Annual Forum.

Subsequently there may be short periods of time where the sound level may vary for any given presentation. During these short intervals, you may want to turn up the speaker volume on your computer

This session was chaired by Lawrence Liberti.

This session is aimed at regulatory writers and publications/medical communications writers who have an interest in preparing communications describing biosimilars products. The objective is to help you recognize differences in communicating about the chemistry, pharmacology, and other characteristics of biosimilars distinct from small molecules and generics.

Session Talks Include:

Biosimilars 101: A Primer - Matthew Frankel
Communicating About Biosimilars: Building on Your Experience – Exploring a New Path - Eileen Girten
Why Biosimilars Matter: Their Global Role in Modern Therapy - Lawrence Liberti

Who should attend?

Medical Communications
Medical Writing
Medical Liaisons
Medical Information
Medical Call Center Environment
Regulatory Affairs
Clinical Research
Professional Education, Training, and Development
Document Management/eSubmissions

Learning objectives

At the conclusion of this webinar, participants should be able to:

Recognize the differences between a biosimilars, small molecule, biologic, and generic product
Describe the special approaches required to communicate regulatory and clinical concepts regarding biosimilars
Discuss the role of biosimilars in global health care

Have an account?

Biosimilars: What the Communicator Should Know About This Growing Field

Overview

Who should attend?

Learning objectives

Be informed and stay engaged.